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Abstract
Background There is a lack of standardised outcomes for haemorrhoidal disease making comparison between trials dif-
icult. A need for a very well validated severity score is essential to facilitate meta-analysis of comparative studies, enabling 
evidence-based clinical practice.
Methods The Hubble trial provides a large cohort of patients with haemorrhoidal disease randomised to rubber band ligation 
(RBL) or haemorrhoidal artery ligation. The haemorrhoid severity score (HSS) was collected on each patient at baseline, 
6 weeks and 1 year after intervention. This allows for the responsiveness of the HSS instrument to be examined and com-
pared with a more speciic instrument, the Vaizey incontinence score (also collected). Responsiveness was tested using four 
methods (efect size, standardised response means (SRM), signiicance of change, and responsiveness statistic).
Results The four tests of responsiveness demonstrated that the HSS was more responsive to changes in the patient’s health 
status following both of the interventions compared to the Vaizey questionnaire. For example, between baseline and 6 weeks, 
the RBL intervention efect size scores and SRM calculations indicated a non-signiicant small amount of change (0.20 and 
0.16 respectively). However, using the HSS, the efect size and SRM demonstrated a large magnitude of change (1.12 and 
1.01, respectively) which was signiicant. Similar results were observed at 1 year. Signiicance of change scores and the index 
of responsiveness were also higher for the HSS questionnaire than the Vaizey across both treatment modalities.
Conclusions The HSS is a highly responsive tool for the detection of changes in haemorrhoid symptoms. It should form an 
essential patient-reported outcome tool for future studies on haemorrhoidal disease.
Keywords Haemorrhoid · Patient-reported outcome · Psychometrics
Introduction
Haemorrhoidal disease is a common condition, and can 
present with symptoms including bleeding, pain and anal 
leakage. There is a range of surgical interventions available 
including rubber band ligation (RBL), haemorrhoid artery 
ligation (HAL), stapled haemorrhoidopexy and excisional 
haemorrhoidectomy, some of which have been assessed in 
randomised trials [1]. Although there have been attempts 
to amalgamate these trials and produce guidance regarding 
optimal treatment pathways, all are subject to interpretation 
and on occasion guidelines difer substantially [2–4]. One 
of the major challenges in the comparison of these difer-
ent studies is the lack of standardised outcomes. Research 
in haemorrhoidal disease is often confounded by the poly-
symptomatic nature of the disease process. Clinician-
reported outcomes in this setting show low levels of inter-
rater agreement, making them unreliable [5].
In benign conditions, quality of life is an important out-
come measure, but is frequently not reported. Where it is 
reported, generic quality of life tools are used that may not 
relect speciically on haemorrhoidal disease [6]. Other stud-
ies may use outcomes that are speciic solely to aspects of 
haemorrhoidal disease such as prolapse or incontinence, and 
fail to capture changes in other outcomes related to haemor-
rhoids [7]. A validated haemorrhoid-speciic outcome tool, 
which takes into account both the poly-symptomatic nature 
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of the disease along with the efect of these symptoms on 
quality of life, is required to be able to compare interven-
tions and guide optimal therapy. Attempts have been made 
to produce such a tool using a multi-symptom approach, the 
haemorrhoid severity score (HSS) introduced by Nystrom 
[6]. Whilst relecting the appropriate symptomatology, this 
scoring system has not gained wide acceptance due probably 
to a lack of robust validation. Others have developed this 
system and validated it (the Sodergren score) but validation 
was based on a very small sample of patients [8].
Responsiveness is an essential quality of any health-
related quality of life (HRQoL) measure and refers to the 
ability of an instrument to detect change over time, if a true 
change in the patient’s health status has occurred before 
and after an intervention or treatment [9]. It also provides 
evidence of an instrument’s validity as it should conirm 
that anticipated responses arise in accordance with corre-
sponding changes in health [10]. The responsiveness of an 
instrument is ideally evaluated using a therapy of known 
efectiveness, such as one evaluated in a clinical trial.
The aim of this study was to establish the responsiveness 
of the HSS for use in the evaluation of patients’ haemor-
rhoids and determine the suitability of the instrument as an 
outcome measure in this context.
Materials and methods
As the responsiveness of an instrument is ideally evalu-
ated using a therapy of known efectiveness [10, 11], this 
validation was planned as a secondary analysis of HuBBLe 
trial data (ISRCTN41394716) [11]. As part of this study, all 
patients had provided informed consent for their data to be 
used for analysis.
The Hubble trial was a multi-centre, parallel group ran-
domised controlled trial with a 1:1 allocation ratio compar-
ing HAL with RBL in adults aged 18 years or over with 
symptomatic second- or third-degree haemorrhoids. The 
primary outcome was deined as the proportion of patients 
with recurrent haemorrhoids at 12 months post-procedure, 
as derived from the patient’s self-reported assessment in 
combination with general practitioner and hospital records. 
Recurrence was deined using a simple question 12 months 
after randomisation [5]. ‘At the moment, do you feel your 
symptoms from your haemorrhoids are: (1) Cured or 
improved compared with before starting treatment; or, (2) 
Unchanged or worse compared with before starting treat-
ment?’. Secondary endpoints assessed at baseline, 6 weeks 
and 12 months included: the haemorrhoid symptom severity 
score as well as the Vaizey incontinence score [12], a VAS 
pain score and health state utility based on the EuroQoL-
5D. The study randomised 185 patients to HAL and 187 
to RBL, and showed 1-year recurrence rates of 49% and 
30%, respectively. Six-month questionnaire data including 
HSS were captured for 137 RBL and 144 HAL patients, 
and 1-year questionnaire data for 125 and 131, respectively.
Statistical analysis
The HSS comprises five items. All items included in a 
domain are scored between 0 and 3 (0 indicating best and 3 
worst health status). A total score is obtained by summing 
the answers to each item. Lower scores indicate better haem-
orrhoidal health.
The Vaizey incontinence score questionnaire is a seven-
item measure shown to outperform others in detecting fae-
cal incontinence [12]. The Vaizey consists of seven items, 
three of which ask about the frequency of incontinence on 
a 4-point scale ranging from 0 = Never to 4 = Daily, fol-
lowed by a single item about the extent to which symptoms 
alter lifestyle (using the same 4-point scale). The inal three 
items are concerned with the severity of incontinence using 
a dichotomous No/Yes response scale (No = 0, Yes = 2 for 
items ive and six, and 4 for item seven). The Vaizey score is 
calculated by summing responses across the seven items. A 
lower score indicates less faecal incontinence (e.g. 0 = per-
fect continence, 24 = totally incontinent).
Numerous methods are available to determine the respon-
siveness of an instrument. As there is no gold standard 
approach, it has been recommended that multiple methods 
are employed [9, 10]. Four diferent statistical analyses were 
used to evaluate the responsiveness of the HSS, including: 
(i) efect size, (ii) standardised response means, (iii) signii-
cance of change, and the (iv) responsiveness statistic. All 
statistical analyses were performed using SPSS version 23 
(IBM Corp, Armonk NY,USA).
Efect size
The efect size (ES) is an estimation of the magnitude of 
change. It is calculated by measuring the diference between 
the means pre- and post-treatment, and dividing this value by 
the standard deviation of the pre-treatment score [13]. The 
changes in health status are translated into a standard unit 
of measurement to aid interpretation. Generally accepted ES 
values are 0.20 (Small), 0.50 (Moderate) and 0.80+ (Large) 
[14]. A small efect size implies that treatment has little 
inluence on the health status of patients as measured by 
that speciic questionnaire or domain.
Standardised response mean
The standardised response mean (SRM) is similar to ES. 
However, to calculate the SRM the mean change in scores 
(i.e. between baseline and follow-up) is divided by the stand-
ard deviation of change in score [10].
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Signiicance of change
The mean changes in domain scores were calculated for 
patients based upon their answers to the anchor question in 
the primary outcome of the trial (whether they felt ‘(i) Cured 
or improved compared with before starting treatment; or, (ii) 
Unchanged or worse compared with before starting treat-
ment?’). These data were collected at 6 weeks and 1 year 
post-treatment.
Responsiveness statistic
The responsiveness statistic compares subjects who report 
improvement following intervention using the two ques-
tions above, with those who report no improvement. It is 
calculated by dividing the mean change in score for patients 
reporting improvement by the SD of scores from those who 
report no improvement [13]. A responsiveness statistic 
value ≥ 1 indicates that an instrument is highly responsive 
to change, and a value of between 0.20 and 1 indicates an 
acceptable level of responsiveness [14].
Results
Demographics from Hubble
The RBL group included 176 participants, 172 of whom 
underwent the intervention. This included 99 (56%) male 
participants and had a mean age of 49.0 years (S.D. 12.9). 
Grade II haemorrhoids were present in 115 (65%) partici-
pants, grade III in 60 (34%) and grade was missing for 1 par-
ticipant. The recurrence rate at 1 year was 49% (87 cases).
The HAL group included 161 participants, 158 of whom 
underwent the intervention. This included 85 (53%) male 
participants and had a mean age of 48.5 years (SD 13.5). 
Grade II haemorrhoids were present in 92 (57%) partici-
pants, grade III in 68 (42%) and grade was missing for 1 par-
ticipant. The recurrence rate at 1 year was 30% (48 cases).
Haemorrhoid outcomes
Most patients felt ‘cured or improved’ following the inter-
ventions (81% at 6 weeks; 72% after 1 year) although some 
patients reported that they felt ‘worse or unchanged’ 6 weeks 
and 1 year after treatment. Ninety-two percent of HAL group 
patients felt cured or improved after 6 weeks compared to 
71% of those in the RBL group. There was little diference 
between the intervention groups at 1 year. Again, 71% of 
the RBL stated that they felt cured or improved compared 
with 73% of the HAL group (representing a decrease in 
positive appraisals from the 6-week self-reported recur-
rence). Responses to the recurrence question are summa-
rised in Table 1.
Efect size and SRM—from baseline to 6 weeks 
(Table 2)
Using the Vaizey score, in the HAL group mean scores from 
baseline to 6 weeks decreased indicating an improvement 
(5.23–4.29). However, these changes were non-signiicant 
(p = 0.075). Efect size and SRM calculations indicated 
a small amount of change (0.20 and 0.16, respectively). 
Using the HSS, a signiicant change was identiied between 
scores at baseline and week 6 (6.48–3.02, p < 0.001). The 
efect size and SRM also demonstrated a large magnitude 
of change (1.12 and 1.01, respectively).
In the RBL group, using the Vaizey, mean scores between 
baseline and 6 weeks in the patient sample improved 
(5.70–3.79) which was signiicant (p < 0.001), with small 
to moderate efect size and SRMs (0.36 and 0.39, respec-
tively). However, using the HSS, whilst a signiicant change 
was also observed (6.35–4.05, p < 0.001), the magnitude of 
change was greater as demonstrated by the efect size (0.75) 
and SRM (0.72).
Efect size and SRM—from baseline to 1 year 
(Table 3)
Using the Vaizey score, for the HAL group mean scores 
from baseline to 1 year signiicantly decreased indicating 
an improvement (5.63–4.61, p = 0.04) but the efect size and 
SRM indicated only the smallest amount of change (0.21 and 
0.21, respectively). Using the HSS, a signiicant change from 
baseline to 1 year was observed (6.18–3.63, p < 0.001). The 
efect size and SRM also demonstrated a large magnitude of 
change (0.85 and 0.76, respectively).
Table 1  Recurrence in RBL and HAL treatment groups at 6  weeks 
and 1 year post-interventions
RBL rubber band ligation, HAL haemorrhoidal artery ligation
Patient’s self-report recur-
rence
All patients RBL HAL
6 Weeks
 ‘Cured or improved’ 237 (81%) 106 (71%) 131 (92%)
 ‘Unchanged or Worse’ 55 (19%) 43 (29%) 12 (8%)
 Total 292 (100%) 149 (100%) 143 (100%)
1 Year
‘ Cured or improved’ 183 (72%) 91 (71%) 92 (73%)
 ‘Unchanged or Worse’ 71 (28%) 37 (29%) 34 (27%)
 Total 254 (100%) 128 (100%) 126 (100%)
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In the RBL group, using the Vaizey, mean scores 
between baseline and 1 year the patient sample improved 
(4.84–3.60) which was signiicant (p = 0.013), with small 
efect sizes and SRMs (0.28 and 0.26, respectively). How-
ever, using the HSS, whilst a signiicant change was also 
observed (6.03–3.62, p < 0.001), the magnitude of change 
was greater as demonstrated by the efect size (0.76) and 
SRM (0.64).
There was no significant difference in either group 
(HAL or RBL) from pre-randomisation score to baseline 
score (Table 4).
Signiicance of change: cured after treatment
The efect size and signiicance of change scores between 
baseline and 6 weeks were derived for patients who had 
undergone HAL and RBL treatment, and reported them-
selves to be ‘cured or improved’ or ‘unchanged or worse’ 
at 6 weeks as based upon their own self-reported answers 
to the recurrence question (Table 5). For the patients who 
rated themselves as ‘cured or improved’ that received the 
HAL intervention, this change was only signiicant using 
the HSS questionnaire (p < 0.001). The efect size and SRM 
Table 2  Mean scores, efect sizes, and signiicance of change (paired t test) between baseline and 6 weeks on the Vaizey and HSS for the two 
treatment groups and overall
RBL rubber band ligation, HAL haemorrhoidal artery ligation, HSS haemorrhoid severity score
N Mean baseline SD N Mean 6 weeks SD Mean diference (SD) Efect size SRM Paired t test
HAL
 Vaizey HAL 126 5.23 4.84 126 4.29 5.12 0.94 (5.90) 0.20 0.16 p = 0.75
 HSS HAL 133 6.48 3.08 133 3.02 2.97 3.47 (3.44) 1.12 1.01 p < 0.001
RBL
Vaizey RBL 102 5.70 5.23 102 3.79 4.55 1.90 (4.83) 0.36 0.39 p < 0.001
HSS RBL 111 6.35 3.08 111 4.05 3.41 2.31 (3.19) 0.75 0.72 p < 0.001
All
Vaizey All 228 5.44 5.01 228 4.07 4.87 1.37 (5.46) 0.27 0.25 p < 0.001
HSS All 244 6.42 3.07 244 3.48 3.21 2.94 (3.37) 0.96 0.87 p < 0.001
Table 3  Mean scores, efect sizes, and signiicance of change (paired t test) between baseline and 1 year on the Vaizey and haemorrhoid severity 
scores for the two treatment groups and overall
RBL rubber band ligation, HAL haemorrhoidal artery ligation, HSS haemorrhoid severity score
N Mean baseline SD N Mean 1 year SD Mean diference (SD) Efect size SRM Paired t test
HAL
Vaizey HAL 98 5.63 4.82 98 4.61 4.76 1.02 (4.91) 0.21 0.21 p = 0.042
HSS HAL 117 6.18 2.99 117 3.63 3.31 2.55 (3.34) 0.85 0.76 p < 0.001
RBL
Vaizey RBL 94 4.84 4.49 94 3.60 4.38 1.25 (4.77) 0.28 0.26 p = 0.013
HSS RBL 104 6.03 3.19 104 3.62 3.31 2.41 (3.79) 0.76 0.64 p < 0.001
All
Vaizey All 192 5.24 4.67 192 4.11 4.60 1.13 (4.83) 0.24 0.23 p = 0.001
HSS All 221 6.11 3.08 221 3.62 3.31 2.48 (3.55) 0.81 0.70 p < 0.001
Table 4  Mean scores, efect sizes, and signiicance of change (paired t test) between pre-randomisation and baseline on the Vaizey and haemor-
rhoid severity scores for the two treatment groups combined
RBL rubber band ligation, HAL haemorrhoidal artery ligation, HSS haemorrhoid severity score
N Mean pre-randomi-
sation
SD N Mean baseline SD Efect size Paired t test
Vaizey 123 5.44 4.99 123 5.47 4.93 0.06 p = 0.875
HSS 127 6.35 3.32 127 6.39 3.23 0.014 p = 0.732
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revealed the magnitude of change to be greater using this 
questionnaire (1.18 and 1.11 respectively) compared to the 
Vaizey Questionnaire which detected only a small amount 
of change (0.24 and 0.21, respectively).
For ‘cured or improved’ patients who underwent the RBL 
intervention, a similar trend was observed. Whilst the mean 
scores demonstrated an improvement in line with the self-
report answers, the efect sizes and SRMs revealed only a 
moderate amount of change using the Vaizey (0.40 and 0.43) 
compared to the HSS which detected a large magnitude of 
change (0.97–0.95, respectively).
In patients who reported themselves to be unchanged or 
worse, no signiicant diferences were observed for either 
the HAL or RBL treatment groups and the magnitude of 
change was small as indicated by the efect sizes and SRMs. 
In the HAL group, the mean scores on the Vaizey indicated 
the patient group had got worse (4.20–6.40) but the mean 
scores on the HSS revealed they had the stayed the same 
(7.50–7.50).
Signiicance of change: cured after treatment (from 
baseline to 6 weeks—cured at 1 year)
The efect size and signiicance of change scores between 
baseline and 6 weeks were calculated as above for patients 
in either intervention group who self-reported that their 
condition was ‘cured or improved’ or ‘unchanged or 
worse’ at 1 year (Table 6). For the ‘cured or improved’ 
patients in the HAL intervention group, this change was 
again only signiicant using the HSS Questionnaire who 
rated themselves as ‘cured or improved’ (p < 0.001). The 
efect size and SRM revealed the magnitude of change 
to be greater using this questionnaire (1.03 and 0.99, 
respectively) compared to the Vaizey Questionnaire which 
detected only a small amount of change (0.16 and 0.13, 
respectively).
This finding was replicated for RBL patients self-
reporting ‘cured or improved’. Whilst the mean scores 
demonstrated an improvement in line with the self-report 
answers, the efect sizes and SRMs revealed only a small 
to moderate amount of change using the Vaizey (0.28 and 
0.28) compared to the HSS which detected a large magni-
tude of change (0.94–1.01, respectively).
Due to the incongruence between the timing of patient 
ratings of changes in health status (cured or not at 1 year) 
and the significance of change period (from baseline 
to 6 weeks), patients in both intervention groups who 
reported ‘unchanged or worse’ condition after 1  year 
showed a decrease in Vaizey and HSS scores at 6 weeks 
(i.e. an improvement). This change in the HAL group was 
only signiicant (p < 0.001) when using the HSS and not 
the Vaizey. The efect size and SRM suggest a large mag-
nitude of change (1.13 and 0.93, respectively).
For patients who reported themselves to be ‘unchanged 
or worse’ in the RBL intervention group, efect sizes and 
SRM were very similar, and small to moderate, for the 
Vaizey (0.31 and 0.40, respectively) and HSS (0.31 and 
0.35, respectively). The change detected by the Vaizey was 
signiicant (p = 0.05).
Table 5  HAL mean scores, efect sizes, and signiicance of change 
(paired t test) between baseline and 6 weeks on the Vaizey and haem-
orrhoid severity scores for the two treatment groups for patients who 
reported themselves to be “cured or improved” and for patients who 
reported themselves to be “unchanged or worse” at 6 weeks
RBL rubber band ligation, HAL haemorrhoidal artery ligation, HSS haemorrhoid severity score
N Mean baseline (SD) Mean 6 weeks (SD) Mean diference Efect size SRM 95% CI Paired t test
Cured or improved
 HAL
  Vaizey HAL 114 5.33 (5.01) 4.11 (5.10) 1.22 (5.94) 0.24 0.21 0.12–2.32 p = 0.30
  HSS HAL 121 6.42 (3.17) 2.67 (2.60) 3.75 (3.38) 1.18 1.11 3.14–4.36 p < 0.001
 RBL
  Vaizey RBL 74 5.26 (4.94) 3.27 (4.42) 1.97 (4.63) 0.40 0.43 0.91–3.06 p < 0.001
  HSS RBL 79 5.94 (3.00) 3.01 (2.81) 2.92 (3.08) 0.97 0.95 2.23–3.61 p < 0.001
Unchanged or Worse
 HAL
  Vaizey HAL 10 4.20 (2.82) 6.40 (5.72) − 2.20 (5.20) − 0.78 − 0.42 From − 5.92 to 1.52 p > 0.05
  HSS HAL 10 7.50 (1.58) 7.50 (3.87) 0.00 (2.58) 0.00 0.00 From − 1.84 to 1.84 p > 0.05
 RBL
  Vaizey RBL 26 6.73 (6.02) 5.58 (4.60) 1.15 (5.21) 0.19 0.22 From − 0.95 to 3.26 p > 0.05
  HSS RBL 30 7.50 (3.06) 6.97 (3.27) 0.53 (2.85) 0.17 0.19 From − 0.53 to 1.60 p > 0.05
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Table 6  Mean scores, efect sizes, and signiicance of change (paired t test) between baseline and 6 weeks on the Vaizey and HSS for the two treatment groups for patients who reported them-
selves to be “cured or improved” and for patients who reported themselves to be “unchanged or worse” at 1 year
RBL rubber band ligation, HAL haemorrhoidal artery ligation, HSS haemorrhoid severity score
N Mean baseline (SD) Mean 6 weeks 
(SD)
Mean diference Efect size SRM 95% CI Paired t test
Cured or improved
 HAL
  Vaizey HAL 73 5.52 (5.08) 4.71 (5.57) 0.81 (6.03) 0.16 0.13 From − 0.60 to 
2.21
p > 0.05
  HSS HAL 78 5.78 (3.21) 2.46 (2.51) 3.32 (3.36) 1.03 0.99 2.56–4.08 p < 0.001
 RBL
  Vaizey RBL 55 4.85 (4.65) 3.55 (4.21) 1.31 (4.69) 0.28 0.28 0.04–2.58 p = 0.04
  HSS RBL 60 6.40 (3.22) 3.37 (3.01) 3.03 (3.01) 0.94 1.01 2.26–3.81 p < 0.001
Unchanged or worse
 HAL
  Vaizey HAL 27 5.56 (4.78) 4.19 (4.49) 1.37 (5.92) 0.29 0.23 From − 0.97 to 
3.71
p > 0.05
  HSS HAL 28 7.29 (2.54) 4.43 (3.05) 2.86 (3.09) 1.13 0.93 1.66–4.05 p < 0.001
 RBL
  Vaizey RBL 27 5.85 (5.80) 4.04 (5.09) 1.82 (4.58) 0.31 0.40 0.00–3.63 p = 0.05
  HSS RBL 28 5.93 (3.25) 4.93 (3.63) 1.00 (2.84) 0.31 0.35 From − 0.10 to 
2.10
p > 0.05
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Signiicance of change: cured after treatment (from 
baseline to 1 year—cured at 1 year) (Table 7)
The efect size and signiicance of change scores between 
baseline and 1 year were also calculated for patients in either 
intervention group who self-reported that their condition 
was ‘cured or improved’ or ‘unchanged or worse’ at 1 year 
(Table 7). For the patients who rated themselves as ‘cured or 
improved’ who underwent the HAL intervention, this change 
was signiicant using both the Vaizey (p < 0.01) and HSS 
(p < 0.001) Questionnaires. Efect size and SRM revealed the 
magnitude of change to be greater using the HSS (1.14 and 
1.13, respectively) compared to the Vaizey Questionnaire 
which detected only a small to moderate amount of change 
(0.32 and 0.32 respectively).
For ‘cured or improved’ patients who underwent the RBL 
intervention, a similar trend was observed. Whilst the mean 
scores demonstrated an improvement in line with the self-
report answers, the efect sizes and SRMs revealed only a 
small to moderate amount of change using the Vaizey (0.33 
and 0.31) compared to the HSS which detected a large mag-
nitude of change (1.01–0.98, respectively).
The findings suggest that patients in both interven-
tion groups who at 1 year rated themselves as ‘unchanged 
or worse’ at 1 year may have experienced a short-lived 
improvement post-intervention (from baseline to 6 weeks). 
The HSS but not Vaizey showed a signiicant large mag-
nitude change for the HAL intervention group, while both 
HSS and the Vaizey detected small improvements for RBL 
patients. This supposition is supported by the signiicance 
of change results between baseline and 1 year for patients 
cured or not also at 1 year (Table 7) showing no signiicant 
changes for ‘unchanged or worse’ patients.
For patients who reported themselves to be ‘unchanged 
or worse’, no signiicant diferences were observed for either 
the HAL or RBL treatment groups and the magnitude of 
change was very small as indicated by the efect sizes and 
SRMs.
Responsiveness statistic
The responsiveness statistic was calculated for the Vaizey 
and HSS for both the HAL and RBL treatment groups 
(Table 8). Values for the responsiveness statistic using the 
Vaizey ranged from 0.23 to 0.38. However, this was much 
higher using the HSS Questionnaire, where the responsive-
ness values ranged between 1.02 and 1.45, indicating that 
this measure was highly responsive to change.
Discussion
This study was a planned secondary analysis of trial data 
undertaken to determine the responsiveness of the HSS in 
the context of RBL and HAL as treatments for haemor-
rhoids. The results indicate that the HSS is more responsive 
to change in patients’ health status than the Vaizey scale for 
both procedures as measured by efect sizes, SRMs, signii-
cance of change scores and the index of responsiveness. The 
instrument, therefore, appears to be suitable for use as an 
outcome measure in this context.
Table 7  Mean scores, efect sizes, and signiicance of change (paired 
t test) between baseline and 1  year on the Vaizey and HSS for the 
two treatment groups for patients who reported themselves to be 
“cured or improved” and for patients who reported themselves to be 
“unchanged or worse” at 1 year
RBL rubber band ligation, HAL haemorrhoidal artery ligation, HSS haemorrhoid severity score
N Mean baseline (SD) Mean 1 year (SD) Mean diference Efect size SRM 95% CI Paired t test
Cured or improved
 HAL
  Vaizey HAL 71 5.35 (4.87) 3.82 (4.44) 1.54 (4.81) 0.32 0.32 0.40–2.67 p < 0.01
  HSS HAL 84 5.69 (3.05) 2.21 (2.12) 3.48 (3.08) 1.14 1.13 2.81–4.14 p < 0.001
 RBL
  Vaizey RBL 68 4.85 (4.36) 3.40 (4.23) 1.46 (4.76) 0.33 0.31 0.31–2.61 p < 0.01
  HSS RBL 74 6.11 (3.22) 2.57 (2.22) 3.54 (3.62) 1.01 0.98 2.70–4.38 p < 0.001
Unchanged or worse
 HAL
  Vaizey HAL 27 6.37 (4.71) 6.70 (5.02) − 0.33 (4.99) − 0.07 − 0.07 − 2.31–1.64 p > 0.05
  HSS HAL 33 7.42 (2.45) 7.24 (3.07) 0.18 (2.79) 0.07 0.06 − 0.81–1.17 p > 0.05
 RBL
  Vaizey RBL 26 4.81 (4.92) 4.12 (4.80) 0.69 (4.86) 0.14 0.14 − 1.27–2.66 p > 0.05
  HSS RBL 30 5.83 (3.16) 6.20 (4.11) − 0.37 (2.59) 0.12 − 0.14 From − 1.34 to 0.60 p > 0.05
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This is perhaps not surprising. The Vaizey scale was 
developed to assess the severity of faecal incontinence and 
not haemorrhoids speciically [12], and so it is reassuring 
that the results of the responsiveness analyses conirmed that 
the HSS measure was more sensitive in detecting changes in 
patients’ health status following treatments for haemorrhoids 
than the Vaizey measure. This adds support to the validity 
of the HSS measure although more tests to determine the 
validity of the measure are needed. The validity of the HSS 
is further supported as the indings of the measure match 
the clinical experience in the use of HAL in the HuBBLe 
trial [11].
There is a wealth of literature about the treatment of 
haemorrhoids. Whilst many publications are case series 
or reviews, there are over 400 randomised controlled trials 
and over 40 meta-analyses. One would, therefore, assume 
that the correct therapy for haemorrhoids should be well 
deined and yet this is not the case. There are a number of 
shortcomings in this ‘high-quality literature’ making it dif-
icult to determine what is the optimal treatment [15]. Sig-
niicant variations in recent guideline recommendations are 
testament to how the evidence can be interpreted diferently 
[2–5]. One major issue with trial data interpretation is the 
lack of standardisation of outcome measures. A systematic 
review by van Tol details over 59 diferent outcome meas-
ures that have been used. They have shown varied deinitions 
of outcomes; in many cases, outcomes were not deined at 
all [15].
There has been a previous attempt at validating a haemor-
rhoid severity score [7, 8]. However, this analysis was based 
on a very small cohort. External validity was demonstrated 
by showing those with higher scores were more likely to 
undergo surgery. There was no demonstration of change with 
time or after treatment. In contrast, we have demonstrated in 
two large cohorts from a carefully designed randomised trial 
that the HSS is highly responsive to intervention and repre-
sents a much more robustly validated tool for the assessment 
of haemorrhoidal treatment that will facilitate comparative 
studies and allow more meaningful synthesis of research 
data.
More recently, a new patient-reported outcome measure 
has been developed to capture the burden associated with 
haemorrhoidal disease and anal issures upon quality of life 
(HEMO-FISS-QoL) [7]. Whilst some psychometric prop-
erties have been determined (e.g. acceptability, construct 
validity and reliability), the responsiveness of this measure 
is yet to be determined. The measure is also not speciic to 
the haemorrhoid population as it is also designed to report 
outcomes following treatment of anal issures. This may 
afect its performance when compared to the HSS.
Strengths and limitations
This analysis does have some limitations. We have only cap-
tured quantitative data. Additional qualitative information 
on participant interpretation of questions as well as ease 
of completion would have been informative. However, the 
form, consisting of ive simple questions, is by no means 
onerous. Another limitation is the fact that the HSS does not 
include a global satisfaction domain. Just because the HSS 
score is improved, this does not indicate that the patient is 
satisied with the outcome and the intervention can be clas-
siied as a ‘success’. An example would be a patient who 
complains of bleeding but also has prolapse. The interven-
tion cures the bleeding but fails to cure the prolapse. Is the 
patient ‘cured’? Nystrom recommended classifying cure as 
an HSS score of 0 or 1 [6]. This is perhaps inadequate to 
capture those who still have symptoms but who are ade-
quately improved so as to be content with the outcome. We, 
therefore, recommend including an additional global satis-
faction score in any haemorrhoidal disease research, such 
as that suggested by Shanmugan et al in a Cochrane review 
[16].
Table 8  Responsiveness 
statistic for the treatment groups 
at 6 weeks and 1 year
HSS haemorrhoid severity score
Measure Mean score change (SD) Respon-
siveness 
statistic“Cured or improved” “Worse or not changed”
HAL
Vaizey (baseline–6 weeks) 1.22 (5.94) − 2.20 (5.20) 0.23
HSS (baseline–6 weeks) 3.75 (3.38) 0.00 (2.58) 1.45
Vaizey (baseline–1 year) 1.54 (4.81) − 0.33 (4.99) 0.31
HSS (baseline–1 year) 3.48 (3.08) 0.18 (2.79) 1.25
RBL
Vaizey (baseline–6 weeks) 1.97 (4.63) 1.15 (5.21) 0.38
HSS (baseline–6 weeks) 2.92 (3.08) 0.53 (2.85) 1.02
Vaizey (baseline–1 year) 1.46 (4.76) 0.69 (4.86) 0.30
HSS (baseline–1 year) 3.54 (3.62) − 0.37 (2.59) 1.37
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Implications for future research
To be able to combine comparative trials in a scientiically 
valid way, a core outcome set of outcomes must be devel-
oped. Van Tol and colleagues are seeking to develop these 
core outcomes via a Delphi exercise [17]. It is very likely 
that the patient-reported outcome domain of this core out-
come set will include the components contained within the 
HSS. Given the poly-symptomatic nature of haemorrhoidal 
disease, a way of combining these patient-reported outcomes 
in a validated and responsive format is required. Our analysis 
clearly shows that the HSS meets these requirements.
Conclusions
The HSS is a highly responsive tool for the detection of 
changes in haemorrhoid symptoms, and should be recom-
mended for use as a patient-reported outcome measure in 
all future clinical trials investigating haemorrhoidal disease.
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